News on Vista Medical Technology from BioPortfolio.com http://www.BioPortfolio.com Consolidated Vista Medical Technology news from BioPortfolio.com Wed, 10 Feb 2010 10:50:44 GMT en RN Rises to Top Position at Sharp Chula Vistahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038919&HITNO=0&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038919&THISHREF=http://c.moreover.com/click/here.pl%3fz2537837122%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038919&HITNO=0&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038919&THISHREF=http://c.moreover.com/click/here.pl%3fz2537837122%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNurse.com: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 ...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039357&HITNO=1&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039357&THISHREF=http://c.moreover.com/click/here.pl%3fz2538057086%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039357&HITNO=1&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039357&THISHREF=http://c.moreover.com/click/here.pl%3fz2538057086%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPipelineReview: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Studyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039880&HITNO=2&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039880&THISHREF=http://c.moreover.com/click/here.pl%3fz2538447157%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039880&HITNO=2&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039880&THISHREF=http://c.moreover.com/click/here.pl%3fz2538447157%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaceuticalProcessing: Ankle Brachial Index System Helps Speed Throughputhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035792&HITNO=3&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035792&THISHREF=http://c.moreover.com/click/here.pl%3fz2536373758%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035792&HITNO=3&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035792&THISHREF=http://c.moreover.com/click/here.pl%3fz2536373758%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDiagnostic & Invasive Cardiology: Anthera signs agreement with FDA for Phase III study of heart drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035503&HITNO=4&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035503&THISHREF=http://c.moreover.com/click/here.pl%3fz2536265114%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035503&HITNO=4&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035503&THISHREF=http://c.moreover.com/click/here.pl%3fz2536265114%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Anthera signs agreement with FDA for Phase III study of heart drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035120&HITNO=5&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035120&THISHREF=http://c.moreover.com/click/here.pl%3fz2536120212%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035120&HITNO=5&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035120&THISHREF=http://c.moreover.com/click/here.pl%3fz2536120212%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTradingMarkets: Amgen Tour of California announces opening leg: Nevada City to Sacramentohttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038328&HITNO=6&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038328&THISHREF=http://c.moreover.com/click/here.pl%3fz2537568547%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038328&HITNO=6&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038328&THISHREF=http://c.moreover.com/click/here.pl%3fz2537568547%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTradingMarkets: Anthera signs agreement with FDA for Phase III study of heart drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037707&HITNO=7&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037707&THISHREF=http://c.moreover.com/click/here.pl%3fz2537245184%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037707&HITNO=7&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037707&THISHREF=http://c.moreover.com/click/here.pl%3fz2537245184%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study;http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034853&HITNO=8&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034853&THISHREF=http://c.moreover.com/click/here.pl%3fz2536014104%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034853&HITNO=8&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034853&THISHREF=http://c.moreover.com/click/here.pl%3fz2536014104%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comHealthcare Sales & Marketing Network: Anthera reports FDA SPA for Phase III Varespladib A-002 studyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033451&HITNO=9&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033451&THISHREF=http://c.moreover.com/click/here.pl%3fz2535208988%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033451&HITNO=9&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033451&THISHREF=http://c.moreover.com/click/here.pl%3fz2535208988%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028586&HITNO=10&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028586&THISHREF=http://c.moreover.com/click/here.pl%3fz2532776262%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028586&HITNO=10&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028586&THISHREF=http://c.moreover.com/click/here.pl%3fz2532776262%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR Newswire: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study;http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028827&HITNO=11&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028827&THISHREF=http://c.moreover.com/click/here.pl%3fz2532865680%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028827&HITNO=11&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028827&THISHREF=http://c.moreover.com/click/here.pl%3fz2532865680%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study;http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028820&HITNO=12&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028820&THISHREF=http://c.moreover.com/click/here.pl%3fz2532862294%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028820&HITNO=12&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028820&THISHREF=http://c.moreover.com/click/here.pl%3fz2532862294%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBreitbart.com: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study;http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028526&HITNO=13&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028526&THISHREF=http://c.moreover.com/click/here.pl%3fz2532746678%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028526&HITNO=13&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028526&THISHREF=http://c.moreover.com/click/here.pl%3fz2532746678%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR Newswire via Yahoo!: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study;http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030796&HITNO=14&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030796&THISHREF=http://c.moreover.com/click/here.pl%3fz2533825184%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030796&HITNO=14&MSIZE=194&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vista%20Medical%20Technology&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030796&THISHREF=http://c.moreover.com/click/here.pl%3fz2533825184%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: